Anti-GABA A Receptor gamma 2 (phospho S327) antibody (ab73183)


  • Product nameAnti-GABA A Receptor gamma 2 (phospho S327) antibody
    See all GABA A Receptor gamma 2 primary antibodies
  • Description
    Rabbit polyclonal to GABA A Receptor gamma 2 (phospho S327)
  • Specificityab73183 is specific for ~45kDa GABA A Receptor gamma 2 subunit phosphorylated at Ser327. Immunolabeling of the GABA A Receptor gamma 2 band is completely blocked by lambda phosphatase treatment.
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Rat
    Predicted to work with: Mouse, Chicken, Cow, Dog, Human, Non Human Primates
  • Immunogen

    Synthetic phosphopeptide corresponding to amino acid residues surrounding the phospho-Ser327 of GABA A Receptor gamma 2.

  • Positive control
    • Rat cortex.


  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
  • Storage bufferPreservative: None
    Constituents: 50% Glycerol, 100µg/ml BSA, 150mM Sodium chloride, 10mM HEPES, pH 7.5
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Purification notesab73183 is prepared from rabbit serum by affinity purification via sequential chromatography on phospho- and dephospho-peptide affinity columns.
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas


Our Abpromise guarantee covers the use of ab73183 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 50 kDa (predicted molecular weight: 54 kDa).


  • FunctionGABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
  • Involvement in diseaseDefects in GABRG2 are the cause of childhood absence epilepsy type 2 (ECA2) [MIM:607681]. ECA2 is a subtype of idiopathic generalized epilepsy (IGE) characterized by an onset at age 6-7 years, frequent absence seizures (several per day) and bilateral, synchronous, symmetric 3-Hz spike waves on EEG. During adolescence, tonic-clonic and myoclonic seizures develop. Some individuals manifest ECA2 occurring in combination with febrile convulsions.
    Defects in GABRG2 are the cause of familial febrile convulsions type 8 (FEB8) [MIM:611277]. A febrile convulsion is defined as a seizure event in infancy or childhood, usually occurring between 6 months and 6 years of age, associated with fever but without any evidence of intracranial infection or defined pathologic or traumatic cause. Febrile convulsions affect 5-12% of infants and children up to 6 years of age. There is epidemiological evidence that febrile seizures are associated with subsequent afebrile and unprovoked seizures in 2% to 7% of patients.
    Defects in GABRG2 are the cause of generalized epilepsy with febrile seizures plus type 3 (GEFS+3) [MIM:604233]. Generalized epilepsy with febrile seizures-plus refers to a rare autosomal dominant, familial condition with incomplete penetrance and large intrafamilial variability. Patients display febrile seizures persisting sometimes beyond the age of 6 years and/or a variety of afebrile seizure types. GEFS+ is a disease combining febrile seizures, generalized seizures often precipitated by fever at age 6 years or more, and partial seizures, with a variable degree of severity.
    Defects in GABRG2 are a cause of severe myoclonic epilepsy in infancy (SMEI) [MIM:607208]; also called Dravet syndrome. SMEI is a rare disorder characterized by generalized tonic, clonic, and tonic-clonic seizures that are initially induced by fever and begin during the first year of life. Later, patients also manifest other seizure types, including absence, myoclonic, and simple and complex partial seizures. Psychomotor development delay is observed around the second year of life. SMEI is considered to be the most severe phenotype within the spectrum of generalized epilepsies with febrile seizures-plus.
  • Sequence similaritiesBelongs to the ligand-gated ion channel (TC 1.A.9) family. Gamma-aminobutyric acid receptor (TC 1.A.9.5) subfamily. GABRG2 sub-subfamily.
  • Post-translational
    Palmitoylated by ZDHHC3/GODZ; which may affect presynaptic clustering and/or cell surface stability.
  • Cellular localizationCell junction > synapse > postsynaptic cell membrane. Cell membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • CAE 2 antibody
    • CAE2 antibody
    • ECA 2 antibody
    • ECA2 antibody
    • GABA(A) receptor gamma 2 antibody
    • GABA(A) receptor subunit gamma 2 antibody
    • GABA(A) receptor subunit gamma-2 antibody
    • GABRG 2 antibody
    • GABRG2 antibody
    • Gamma aminobutyric acid (GABA) A receptor gamma 2 antibody
    • Gamma aminobutyric acid A receptor gamma 2 antibody
    • Gamma aminobutyric acid receptor gamma 2 subunit antibody
    • Gamma-aminobutyric acid receptor subunit gamma-2 antibody
    • GBRG2_HUMAN antibody
    • GEFSP 3 antibody
    • GEFSP3 antibody
    see all

Anti-GABA A Receptor gamma 2 (phospho S327) antibody images

  • All lanes : Anti-GABA A Receptor gamma 2 (phospho S327) antibody (ab73183) at 1/1000 dilution

    Lane 1 : Rat cortex
    Lane 2 : Rat cortex with immunising peptide

    Predicted band size : 54 kDa
    Observed band size : 50 kDa (why is the actual band size different from the predicted?)
    Additional bands at : 100 kDa,95 kDa. We are unsure as to the identity of these extra bands.

References for Anti-GABA A Receptor gamma 2 (phospho S327) antibody (ab73183)

ab73183 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab73183.
Please use the links above to contact us or submit feedback about this product.